What is ICD-10 code C92.32?

C92.32 is the ICD-10-CM diagnosis code for Myeloid sarcoma, in relapse. A solid tumor made of myeloid cancer cells that has returned after remission. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C92.32 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C92.32 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C92.32 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C92.32 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Which HCC does C92.32 map to under V28?

C92.32 maps to CMS-HCC V28 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic). The category number and label come from the CMS-HCC V28 model file for payment year 2026.

What does C92.32 pay in RAF?

C92.32 carries a community, non-dual, aged (CNA) RAF weight of 4.209 under CMS-HCC V28 for payment year 2026. The weight comes from the CMS V28 relative-factor file, not a hand-typed table.

What is the V28 vs V24 difference for C92.32?

CMS phased in the V28 risk adjustment model over payment years 2024 (33%), 2025 (67%), and 2026 (100%), replacing V24. V28 consolidates HCC categories, removes some lower-acuity conditions, and recalibrates RAF weights across the entire model. For C92.32, V28 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic at RAF 4.209 while V24 mapped to Lung and Other Severe Cancers at RAF 1.024. Both models can still appear in legacy data and in payer-specific lookback periods.

2026 ICD-10-CM C92.32: Myeloid sarcoma, in relapse

C92.32 maps to CMS-HCC V28 17 (RAF 4.209). Documentation must support MEAT. MEAT criteria · RAF calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC92.32Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C92.32

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Myeloid sarcoma, in relapse

A solid tumor made of myeloid cancer cells that has returned after remission.

Buddy Insight

Myeloid sarcoma in relapse indicates recurrence of the extramedullary myeloid tumor after previously achieving remission.

CMS-HCC V28

Mapped

HCC 17

Cancer Metastatic to Lung, Li...

RAF 4.209

CMS-HCC V24

Mapped

HCC 9

Lung and Other Severe Cancers

RAF 1.024

ACA/HHS

Mapped

HCC 9

HHS-HCC 9

Varies by metal level

ESRD/PACE

Mapped

HCC 9

Lung and Other Severe Cancers

RAF 0.181

RXHCC

Mapped

HCC 19

Lymphoma and Other Cancers

RAF 1.949

Code Book Path

Official

C92Myeloid leukemia

C92.3Myeloid sarcoma

C92.32Myeloid sarcoma, in relapse

Inclusion Terms

Official

A malignant tumor of immature myeloid cells
Chloroma
Granulocytic sarcoma

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C92.32 in this effective period.

Related Child Codes

Official

C92.30Myeloid sarcoma, not having achieved remission

C92.31Myeloid sarcoma, in remission

Includes

Official

ICD-10-CM does not list Includes notes for C92.32 in this effective period.

Excludes 1

Official

ICD-10-CM does not list Excludes 1 notes for C92.32 in this effective period.

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C92.32 in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C92.32 in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C92.32 in this effective period.

Buddy Documentation Tip

HCC Buddy guidance

Documentation must confirm prior remission and evidence of recurrent disease, including new or growing extramedullary masses confirmed by biopsy as myeloid sarcoma.

Updated bone marrow biopsy to assess for concurrent AML should be documented.

Imaging studies showing relapse, cytogenetic/molecular testing at relapse, and salvage treatment plan must be recorded.

The site(s) of relapse should be clearly documented.

MEAT Support

HCC Buddy guidance

Documentation must confirm prior remission and evidence of recurrent disease, including new or growing extramedullary masses confirmed by biopsy as myeloid sarcoma.

Updated bone marrow biopsy to assess for concurrent AML should be documented.

Imaging studies showing relapse, cytogenetic/molecular testing at relapse, and salvage treatment plan must be recorded.

The site(s) of relapse should be clearly documented.

Audit Caution

HCC Buddy guidance

Confirm relapse with tissue biopsy rather than imaging alone, as other entities can mimic myeloid sarcoma radiographically.

Relapse at a new anatomic site still qualifies as relapsed myeloid sarcoma.

Transformation to AML in the bone marrow after prior isolated myeloid sarcoma represents a specific clinical scenario that should be clearly documented.

Do not assume the same cytogenetic profile at relapse as at initial diagnosis.

Common Mistakes

HCC Buddy guidance

C92.30 (myeloid sarcoma not in remission) is for primary refractory disease.

C92.31 (myeloid sarcoma in remission) is for controlled disease.

C92.02 (AML in relapse) should be used if relapse is purely bone marrow-based without extramedullary disease.

When both myeloid sarcoma and bone marrow AML relapse occur simultaneously, both codes may be appropriate.

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C92.32 an HCC code?

Yes. C92.32 (Myeloid sarcoma, in relapse) maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic under the CMS-HCC V28 risk adjustment model (and Lung and Other Severe Cancers under V24), with a community non-dual aged RAF of 4.209. It is billable for payment year 2026.

Coder answer: C92.32 is billable and maps to V28 HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code: C92.32
Description: Myeloid sarcoma, in relapse
HCC (V28): HCC 17 — Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
RAF: 4.209
Billable: Yes
Payment year: 2026

HCC Category Mapping

V28HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic

4.209

V24HCC 9, Lung and Other Severe Cancers

1.024

ESRDHCC 9, Lung and Other Severe Cancers

0.181

RxHCCHCC 19, Lymphoma and Other Cancers

1.949

Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

Work C92.32 in the Code Book — tabular path, V28 RAF, and MEAT checklist →

MEAT Criteria for C92.32

For C92.32 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C92.32 during that encounter, not just copy-forwarded from a problem list.

Coder workflow notes

Get the V28 RAF + MEAT cheat sheet

One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C92.32 is the ICD-10-CM diagnosis code for myeloid sarcoma, in relapse. A solid tumor made of myeloid cancer cells that has returned after remission. C92.32 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C92.32 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic (HCC 17) with a community, non-dual, aged base RAF weight of 4.209. Under the older CMS-HCC V24 model, C92.32 maps to Lung and Other Severe Cancers (HCC 9) with a community, non-dual, aged base RAF weight of 1.024. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Ensure relapse is clearly documented and distinguish from initial presentation. Because C92.32 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C92.32 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Ensure relapse is clearly documented and distinguish from initial presentation
•Note the site of the myeloid sarcoma in the medical record

Clinical Significance

Myeloid sarcoma in relapse indicates recurrence of the extramedullary myeloid tumor after previously achieving remission. Relapsed myeloid sarcoma may recur at the original site, at new extramedullary locations, or as bone marrow-based AML. Treatment of relapsed disease typically requires salvage chemotherapy and consideration of allogeneic stem cell transplantation for eligible patients.

Documentation Requirements

✓Documentation must confirm prior remission and evidence of recurrent disease, including new or growing extramedullary masses confirmed by biopsy as myeloid sarcoma.
✓Updated bone marrow biopsy to assess for concurrent AML should be documented.
✓Imaging studies showing relapse, cytogenetic/molecular testing at relapse, and salvage treatment plan must be recorded.
✓The site(s) of relapse should be clearly documented.

Commonly Confused Codes

•C92.30 (myeloid sarcoma not in remission) is for primary refractory disease.
•C92.31 (myeloid sarcoma in remission) is for controlled disease.
•C92.02 (AML in relapse) should be used if relapse is purely bone marrow-based without extramedullary disease.
•When both myeloid sarcoma and bone marrow AML relapse occur simultaneously, both codes may be appropriate.